R&D News | pharmaphorum

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

Could high HDL-cholesterol raise dementia risk?

A new study has added to data suggesting that HDL cholesterol (HDL-c) – sometimes called ‘good’ cholesterol, as it can help protect against heart disease – may be a risk f

News

Astellas builds case for menopause drug fezolinetant

New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts

News

UK Biobank releases largest-ever genome sequencing dataset

After five years of painstaking lab work, more than 350,000 hours of genome sequencing and £200 million ($253 million) in investment, UK Biobank has completed and released the full se

News

AbbVie cues up filing for c-Met ADC in lung cancer

AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a

News

Start-up Cradle tucks in $24m for protein engineering AI

Dutch-Swiss start-up Cradle has raised €22 million ($24 million) in first-round financing to develop its generative artificial intelligence (GenAI) and synthetic biology p

AbbVie agrees $10.1bn deal to buy ImmunoGen

Could high HDL-cholesterol raise dementia risk?

Astellas builds case for menopause drug fezolinetant

UK Biobank releases largest-ever genome sequencing dataset

AbbVie cues up filing for c-Met ADC in lung cancer

Start-up Cradle tucks in $24m for protein engineering AI

Novartis falls sharply on another major R&D setback

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks